Analysis Of Phase III Study Showed Rituxan(R) Plus Methotrexate Reduced Joint Damage In Rheumatoid Arthritis Patients Who Respond Inadequately To TNF

... Genentech, Inc. (NYSE: DNA) and Biogen Idec, Inc.(Nasdaq: BIIB) today announced positive results from an analysis of REFLEX,a Phase III clinical study of Rituxan(R) (Rituximab) in patients withrheumatoid arthritis (RA) who have had an inadequate response to previoustreatment with one or more tumor necrosis factor (TNF) antagonisttherapies. [click link for full article] ...